The article reviews the emerging role of bacteriophage-based therapeutics in combating antibiotic resistance. Bacteriophages (BPs), natural bacterial predators, offer a promising alternative to treat infections caused by antibiotic-resistant pathogens. The review highlights the effectiveness of BP therapy, particularly when integrated with conventional antibiotics, and discusses various treatment strategies for systemic and localized infections. It also explores the formulation and delivery methods of BPs, including polymeric encapsulation, liposome-encapsulation, microneedle platforms, and electrospun biopolymer fibers. The review emphasizes the advantages of BP-based therapies over antibiotics, such as reduced resistance development and synergistic effects with antibiotics. Additionally, it discusses the potential of antimicrobial BP-derived proteins and the preclinical and clinical progress of BP-based therapeutics against clinically significant pathogens. The article concludes by addressing factors to consider in BP therapy, including biofilm control, formulation, resistance, and pharmacodynamic properties. Overall, BP-based therapies present a personalized and potent solution to the global challenge of antibiotic resistance.The article reviews the emerging role of bacteriophage-based therapeutics in combating antibiotic resistance. Bacteriophages (BPs), natural bacterial predators, offer a promising alternative to treat infections caused by antibiotic-resistant pathogens. The review highlights the effectiveness of BP therapy, particularly when integrated with conventional antibiotics, and discusses various treatment strategies for systemic and localized infections. It also explores the formulation and delivery methods of BPs, including polymeric encapsulation, liposome-encapsulation, microneedle platforms, and electrospun biopolymer fibers. The review emphasizes the advantages of BP-based therapies over antibiotics, such as reduced resistance development and synergistic effects with antibiotics. Additionally, it discusses the potential of antimicrobial BP-derived proteins and the preclinical and clinical progress of BP-based therapeutics against clinically significant pathogens. The article concludes by addressing factors to consider in BP therapy, including biofilm control, formulation, resistance, and pharmacodynamic properties. Overall, BP-based therapies present a personalized and potent solution to the global challenge of antibiotic resistance.